Recently, the UK-based brand valuation consultancy Brand Finance released its "Healthcare 2026" report on global healthcare brand value. CSPC PHARMA secured a position in the "Top 50 most valuable Pharma brands" list, underscoring its robust brand influence. This recognition highlights the company's international standing in brand value, innovation capabilities, and global reach. As an international innovation-driven enterprise integrating R&D, production, and sales of novel drugs, CSPC PHARMA remains committed to its mission of developing quality medicines for China and benefiting people worldwide. The company pursues a dual strategy of innovation and internationalization, deeply engaging in the pharmaceutical industry. It has established a globally integrated R&D system focused on core therapeutic areas including oncology, neuropsychiatry, and cardiovascular diseases. Annual R&D investment continues to increase, with over 200 innovative drug and novel formulation projects in the pipeline. Several of its core products have received national-level science and technology awards. In brand development, CSPC PHARMA adheres to the principles of innovation as its core and quality as its foundation. It maintains a comprehensive quality control system across the entire industrial chain. Its product sales network spans more than 110 countries and regions worldwide, safeguarding global patient health with safe, effective, and high-quality medicines. Consequently, its brand reputation and market competitiveness are steadily strengthening. Moving forward, CSPC PHARMA will continue to deepen its commitment to innovative drug R&D, accelerate its international expansion, and further enhance its global brand influence. The company aims to contribute to the "Healthy China" initiative with higher-quality pharmaceutical products and support Chinese pharmaceutical enterprises in achieving greater prominence on the world stage.